Intelligencia AI
Intelligencia AI helps pharmaceutical and biotech teams understand and lower the risk of clinical trials and development decisions in simple terms. The company offers a B2B SaaS platform that applies machine learning and AI to aggregate life-sciences data, generate predictive risk scores, and surface interpretable drivers of trial and strategy risk. Its product combines data ingestion, ML models, and interpretability tools to produce actionable insights for go/no‑go decisions and trial design. Intelligencia AI works with large global pharmaceutical companies as well as mid-size and smaller biotech firms to accelerate development decision-making.
Intelligencia AI
Intelligencia AI helps pharmaceutical and biotech teams understand and lower the risk of clinical trials and development decisions in simple terms. The company offers a B2B SaaS platform that applies machine learning and AI to aggregate life-sciences data, generate predictive risk scores, and surface interpretable drivers of trial and strategy risk. Its product combines data ingestion, ML models, and interpretability tools to produce actionable insights for go/no‑go decisions and trial design. Intelligencia AI works with large global pharmaceutical companies as well as mid-size and smaller biotech firms to accelerate development decision-making.
TL;DR
Founded: 2017
Headquarters / Offices: New York (offices in San Francisco and Athens)
Domain: Biotechnology / life-sciences AI SaaS
Product focus: AI-powered platform for predicting probability-of-success and de-risking clinical development
Recent notable funding: Series A announced Aug 10, 2021 (reported $12M; lead: MTIP AG)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Clinical drug development decision support; forecasting technical and regulatory outcomes to de-risk trials and portfolio decisions.
Founded
2017
Industry
Biotechnology
Tech Stack
Funding Track Record
12000000
Reported as an oversubscribed Series A; participating investors include Big Pi Ventures and Synetro Group; reported amount $12M.
Investor Signal
“Backed by healthtech and strategic investors including MTIP AG, ZS Associates, Synetro Group, Big Pi Ventures”